



Date: December 14, 2020
To: All Zones
From: Alberta Precision Laboratories (APL) – North Sector, University of Alberta Hospital
Re: New Maternal Prenatal Screen Requisition

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:

- **Effective immediately a revised Maternal Prenatal Screen Requisition is available for use**

Why this is important:

- This requisition reflects new data requirements for prenatal screening including:
 - Chorionicity information for twin pregnancies
 - Induction agent used for ovulation induction (where applicable)
 - Targeted questions regarding medications
 - Specimen ID label space
- Updated to reflect test name changes in ConnectCare
 - First Trimester Prenatal Risk Assessment
 - Second Trimester Prenatal Risk Assessment
- The new requisition must be used and the new fields completed to ensure accurate risk assessment and to avoid delays in patient testing and reporting

Action Required:

- Discard outdated copies of the Maternal Prenatal Screen Requisition (First and Second Trimester)
- The revised requisition can be obtained from the APL or DynaLIFE websites or at [Maternal Prenatal Screen Requisition \(First or Second Trimester Risk Assessment\)](#)

North and Edmonton Zones:

- Use this requisition for the following tests: First Trimester Prenatal Screen (FTPS), Second Trimester Maternal Serum Quad Screen (MOM), and Second Trimester AFP for open neural tube defect screening (MOMA)

Central Zone:

- Use this requisition for the following tests: First Trimester Prenatal Screen (FTPS), Second Trimester Maternal Serum Quad Screen (MOM), and Second Trimester AFP for open neural tube defect screening (MOMA) if the sample is being shipped to Edmonton for testing.

Calgary and South Zone:

- Use this requisition to order Second Trimester Maternal Serum Quad Screen (MOM) and Second Trimester AFP for open neural tube defect screening (MOMA).

Inquiries and feedback may be directed to:

- Genetic Counsellors, University of Alberta Hospital, 780-407-7907
- Miranda Brun, PhD, Clinical Biochemist, University of Alberta Hospital, APL, 780-722-4123, Miranda.Brun2@albertaprecisionlabs.ca

This bulletin has been reviewed and approved by:

- Dr. Kareena Schnabl, Section Chief, Clinical Biochemistry, APL North Sector
- Dr. Michael Mengel, Medical Director, APL North Sector
- Dr. Dennis Bulman, Medical/Scientific Director, Genetics and Genomics, APL